年轻高危霍奇金淋巴瘤的治疗选择——附2例报告并文献复习  

Therapy for Hodgkin's lymphoma in young and high risk group:two cases report and literature review

作　　者：李倩[1] 刘素[1] 马静[1] 杨洪亮[1] 赵海峰[1] 于泳[1] 王晓芳[1] 张翼鷟[1] 王亚非[1] 

机构地区：[1]天津医科大学肿瘤医院血液科国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室,天津300060

出　　处：《临床血液学杂志》2014年第5期801-804,共4页Journal of Clinical Hematology

摘　　要：霍奇金淋巴瘤（Hodgkin＇s lymphoma,HL）在美国约占淋巴瘤总数的11.7%,在我国约占8.54%,是所有成人肿瘤中预后最好的。随着治疗策略的不断改进,在西方发达国家,HL早期患者治疗后5年总生存率（OS）约90.8%,进展期患者的5年OS亦能达到80%以上。In this paper,we demonstrated our strategy for the treatment with Hodgkin＇s lymphoma（HL）by2case reports.Case 1was one 24 years old female who suffered from refractory classical HL with mediastinal mass.She received several cycles of chemoradiotherapy including rituximab and bortezomib,but unfortunately she died for disease progression.Case 2was one 27 years old male whose International Prognostic Score（IPS）was 5points.He received 4cycles of escalated BEACOPP combined with Involved-Field Radiation Therapy（IFRT）,subsequently received auto-stem-cell transplantation（ASCT）as a consolidation therapy.And the curative effect was capable to accept.Therefore,we recommend that for the young HL patients with high risk factors,ASCT is a safe and effective consolidation therapy.

关 键 词：霍奇金淋巴瘤 治疗 

分 类 号：R733.4[医药卫生—肿瘤]